Vor Biopharma Inc. financial data

Symbol
VOR on Nasdaq
Location
Boston, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 477% % -34%
Debt-to-equity -118% % -394%
Return On Equity 275% %
Return On Assets -1546% % -2040%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10,410,630 shares -85%
Common Stock, Shares, Outstanding 9,026,922 shares -87%
Entity Public Float $44,896,947 USD -67%
Common Stock, Value, Issued $15,000 USD 114%
Weighted Average Number of Shares Outstanding, Basic 6,681,794 shares 95%
Weighted Average Number of Shares Outstanding, Diluted 6,681,794 shares 95%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $327,690,000 USD 269%
General and Administrative Expense $39,303,000 USD 35%
Operating Income (Loss) $366,993,000 USD -211%
Nonoperating Income (Expense) $1,298,765,577 USD -23565%
Net Income (Loss) Attributable to Parent $2,449,551,000 USD -2078%
Earnings Per Share, Basic -127 USD/shares -1270%
Earnings Per Share, Diluted -127 USD/shares -1270%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $160,462,000 USD 204%
Marketable Securities, Current $10,000,000 USD -0.11%
Cash, Cash Equivalents, and Short-term Investments $170,500,000 USD 171%
Other Assets, Current $1,277,000 USD 348%
Assets, Current $172,486,000 USD 156%
Property, Plant and Equipment, Net $271,000 USD -96%
Operating Lease, Right-of-Use Asset $3,043,000 USD -92%
Other Assets, Noncurrent $269,000 USD -89%
Assets $176,237,000 USD 52%
Accounts Payable, Current $885,000 USD -33%
Employee-related Liabilities, Current $3,026,000 USD -27%
Accrued Liabilities, Current $17,702,000 USD 100%
Liabilities, Current $18,839,000 USD 31%
Operating Lease, Liability, Noncurrent $2,807,000 USD -90%
Liabilities $2,401,724,000 USD 5481%
Accumulated Other Comprehensive Income (Loss), Net of Tax $12,000 USD -82%
Retained Earnings (Accumulated Deficit) $2,875,833,000 USD -575%
Stockholders' Equity Attributable to Parent $2,225,487,000 USD -3150%
Liabilities and Equity $176,237,000 USD 52%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $31,066,000 USD -2%
Net Cash Provided by (Used in) Financing Activities $606,000 USD -731%
Net Cash Provided by (Used in) Investing Activities $230,000 USD -101%
Common Stock, Shares Authorized 800,000,000 shares 100%
Common Stock, Shares, Issued 9,026,922 shares -87%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $31,902,000 USD -335%
Deferred Tax Assets, Valuation Allowance $139,216,000 USD 33%
Deferred Tax Assets, Gross $149,343,000 USD 29%
Operating Lease, Liability $3,059,000 USD -91%
Depreciation $4,610,000 USD 28%
Payments to Acquire Property, Plant, and Equipment $231,000 USD 103%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $2,449,607,000 USD -2085%
Lessee, Operating Lease, Liability, to be Paid $40,206,000 USD -14%
Property, Plant and Equipment, Gross $272,000 USD -99%
Operating Lease, Liability, Current $252,000 USD -94%
Lessee, Operating Lease, Liability, to be Paid, Year Two $6,681,000 USD 0.45%
Lessee, Operating Lease, Liability, to be Paid, Year One $6,652,000 USD 0.93%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure -24%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $8,376,000 USD -25%
Lessee, Operating Lease, Liability, to be Paid, Year Three $6,882,000 USD 3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $7,088,000 USD 3%
Operating Lease, Payments $1,688,000 USD 3%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $10,127,000 USD -13%
Share-based Payment Arrangement, Expense $13,515,000 USD 35%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%